Physician profile
Steven Simon
NPI 1154329472
$3,968.34
in general payments reported to CMS, 2019-2025
30 companies · $637 in 2025
The $637 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $406 · 2020: $404 · 2021: $731 · 2022: $474 · 2023: $666 · 2024: $652 · 2025: $637.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,954.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,953.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $455.22 | 2021-2025 | Rinvoq, Skyrizi |
| Janssen Biotech, INC. | $426.56 | 2020-2025 | Tremfya |
| Sun Pharmaceutical Industries INC. | $380.84 | 2019-2025 | Winlevi, Ilumya |
| Pfizer INC. | $343.74 | 2019-2025 | |
| Amgen INC. | $300.75 | 2020-2024 | Otezla |
| Lilly USA, LLC | $282.95 | 2019-2024 | Taltz, Olumiant |
| Regeneron Healthcare Solutions, INC. | $272.21 | 2019-2024 | Dupixent |
| Dermavant Sciences, INC. | $259.60 | 2022-2024 | Vtama |
| Incyte Corporation | $225.69 | 2022-2025 | Opzelura |
| Genzyme Corporation | $190.98 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $144.51 | 2019-2022 | |
| Organon LLC | $125.64 | 2025 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $91.40 | 2025 | Sotyktu |
| Leo Pharma INC. | $65.86 | 2019-2024 | Adbry |
| Verrica Pharmaceuticals INC. | $46.87 | 2023-2024 | Ycanth |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vyne Pharmaceuticals INC. | $39.73 | 2020-2021 | |
| Celgene Corporation | $38.85 | 2019 | |
| Almirall LLC | $36.54 | 2021 | |
| Botanix Sb INC | $26.63 | 2025 | Sofdra |
| Sebela Pharmaceuticals INC. | $24.40 | 2019 | |
| Mayne Pharma Commercial LLC | $23.25 | 2019 | |
| Galderma Laboratories, L.P. | $22.54 | 2025 | Nemluvio |
| Aclaris Therapeutics, INC. | $21.59 | 2019 | |
| Strata Skin Sciences, INC. | $20.34 | 2025 | Xtrac |
| Ucb, INC. | $20.21 | 2021 | |
| Promius Pharma LLC | $18.17 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $18.12 | 2022 | |
| Taro Pharmaceuticals USA, INC. | $16.10 | 2019 | |
| Genentech USA, INC. | $14.60 | 2019 | |
| Journey Medical Corporation | $14.45 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Simon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.